fingolimod hydrochloride has been researched along with Optic Neuritis in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Adil, MS; Alfarhan, M; Candadai, AA; Fagan, SC; Liu, F; Narayanan, SP; Somanath, PR; Verma, A | 1 |
| Albert, C; Bellmann-Strobl, J; Brandt, AU; Chien, C; Dörr, J; Hoffmann, O; Liekfeld, A; Mikolajczak, J; Nowak, C; Paul, F; Piper, SK; Scheel, M; Zimmermann, HG | 1 |
| Doi, H; Fukai, R; Higashiyama, Y; Morihara, K; Nakamura, H; Takahashi, K; Takahashi, T; Takeuchi, H; Tanaka, F | 1 |
| Cross, AH; George, A; Lai, S; Lin, TH; Song, C; Song, SK; Sun, P; Wallendorf, M; Yang, R; Ye, Z; Zhan, J | 1 |
| Ahn, SW; Cho, JY; Huh, SY; Hyun, JW; Kim, BJ; Kim, HJ; Kim, SH; Kim, W; Lee, SH; Park, MS | 1 |
| Bowen, JD | 1 |
| Abouzeid, N; Al-Jumah, M; Alroughani, R; Alsaadi, T; Alsharoqi, I; Bohlega, S; Dahdaleh, M; ElKallab, K; Hashem, S; Inshasi, J; Khoury, S; Tawfeek, T; Yamout, B; Zakaria, M | 1 |
| Francis, CE | 1 |
| Aktas, O; Finis, D; Geerling, G; Guthoff, R; Harmel, J; Hartung, HP; Ringelstein, M; Schröder, K | 1 |
| Maeda, Y; Miyazaki, T; Motomura, M; Nakajima, H; Shiraishi, H; Tanaka, K; Tsujino, A | 1 |
| Bähr, M; Diem, R; Hein, K; Hillgruber, C; Kretzschmar, B; McRae, BL; Rau, CR; Sättler, MB | 1 |
2 review(s) available for fingolimod hydrochloride and Optic Neuritis
| Article | Year |
|---|---|
Highly Aggressive Multiple Sclerosis.
Topics: Adult; Age Factors; Alemtuzumab; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Natalizumab; Optic Neuritis; Sex Factors; Treatment Failure | 2019 |
Visual issues in multiple sclerosis.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Macular Edema; Multiple Sclerosis; Neuromyelitis Optica; Nystagmus, Pathologic; Ocular Motility Disorders; Optic Neuritis; Prognosis; Propylene Glycols; Sphingosine; Uveitis | 2013 |
1 trial(s) available for fingolimod hydrochloride and Optic Neuritis
| Article | Year |
|---|---|
Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) - preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial.
Topics: Adult; Evoked Potentials, Visual; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1b; Male; Middle Aged; Optic Neuritis | 2020 |
8 other study(ies) available for fingolimod hydrochloride and Optic Neuritis
| Article | Year |
|---|---|
Neuroprotective Effects of Fingolimod in a Cellular Model of Optic Neuritis.
Topics: Animals; bcl-X Protein; Caspase 3; Cell Death; Cell Survival; Fingolimod Hydrochloride; Mitochondrial Dynamics; Mitochondrial Proteins; Models, Biological; Neurons; Neuroprotective Agents; Optic Neuritis; Rats; Reactive Oxygen Species; Signal Transduction; Stress, Physiological; Tumor Necrosis Factor-alpha | 2021 |
Case Report: Anti-MOG Antibody Seroconversion Accompanied by Dimethyl Fumarate Treatment.
Topics: Adult; Aged; Autoantibodies; Biomarkers; Dimethyl Fumarate; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunity, Humoral; Immunosuppressive Agents; Male; Myelin-Oligodendrocyte Glycoprotein; Myelitis, Transverse; Optic Neuritis; Recurrence; Seroconversion; Steroids; Treatment Outcome | 2021 |
Diffusion basis spectrum imaging measures anti-inflammatory and neuroprotective effects of fingolimod on murine optic neuritis.
Topics: Animals; Anti-Inflammatory Agents; Diffusion Tensor Imaging; Female; Fingolimod Hydrochloride; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Optic Neuritis | 2021 |
Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome.
Topics: Adolescent; Adult; Crotonates; Demyelinating Diseases; Disease Progression; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Nitriles; Oligoclonal Bands; Optic Neuritis; Quinolones; Reproducibility of Results; Republic of Korea; Sensitivity and Specificity; Time Factors; Toluidines; Young Adult | 2019 |
Consensus guidelines for the diagnosis and treatment of multiple sclerosis.
Topics: Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Middle East; Multiple Sclerosis; Myelitis; Natalizumab; Optic Nerve Diseases; Optic Neuritis; Propylene Glycols; Sphingosine; Spinal Cord Diseases | 2013 |
Acetazolamide therapy in a case of fingolimod-associated macular edema: early benefits and long-term limitations.
Topics: Acetazolamide; Administration, Oral; Female; Fingolimod Hydrochloride; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Immunosuppressive Agents; Macular Edema; Multiple Sclerosis, Relapsing-Remitting; Optic Neuritis; Visual Acuity; Young Adult | 2015 |
A case of recurrent optic neuritis associated with cerebral and spinal cord lesions and autoantibodies against myelin oligodendrocyte glycoprotein relapsed after fingolimod therapy.
Topics: Adolescent; Autoantibodies; Brain; Female; Fingolimod Hydrochloride; Humans; Infusions, Intravenous; Magnetic Resonance Imaging; Methylprednisolone; Myelin-Oligodendrocyte Glycoprotein; Myelitis; Optic Neuritis; Recurrence; Spinal Cord | 2016 |
Anti-inflammatory effects of FTY720 do not prevent neuronal cell loss in a rat model of optic neuritis.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Cytokines; Disease Models, Animal; Electrophysiology; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Glycoproteins; Immunosuppressive Agents; Myelin Sheath; Neurons; Oligodendroglia; Optic Neuritis; Propylene Glycols; Rats; Sphingosine | 2011 |